ArticleJournal of biomolecular techniques : JBT2022
Clinical Validation of an Alternative Specimen Collection Kit for SARS-CoV-2 Testing at Fox Chase Cancer Center.
Don A Baldwin, Cheyenne R Gigli, Tim Kwok, Sharon Connelly, James L Helstrom, Barbara Ebersole, Eric A Ross, Michael Araten, Joel Glickman, Robert Glickman and 1 more
Open access · diamondAbstract read
In one paragraphArticle in Journal of biomolecular techniques : JBT, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors at 3 institutions in 1 country.
Don A BaldwinDepartment of Pathology Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania19111 USA.
Cheyenne R GigliDepartment of Pathology Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania19111 USA.
Tim KwokCell Culture Facility Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania19111 USA.
Sharon ConnellyCell Culture Facility Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania77030 USA.
James L HelstromDivision of Anesthesiology Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania19111 USA.
Barbara EbersoleSpeech Pathology and Audiology University of Texas M.D. Anderson Cancer Center HoustonTexas19440 USA.
Eric A RossBiostatistics and Bioinformatics Facility Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania19111 USA.
Michael AratenThe Rodon Group Hatfield Pennsylvania USA.
Joel GlickmanThe Rodon Group Hatfield Pennsylvania USA.
Robert GlickmanThe Rodon Group Hatfield Pennsylvania USA.
Eric M HorwitzDepartment of Radiation Oncology Fox Chase Cancer Center - Temple Health PhiladelphiaPennsylvania USA.
Fox Chase Cancer Center · USTemple University Health System · USThe University of Texas MD Anderson Cancer Center · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8MTUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221705 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI Yin Tan · 2018 to 2026
$16.3MYale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI TOWNSEND, JEFFREY PETER · 2020 to 2024
$11.8MTIC10 anti-tumor effect through regulation of Foxo3a and TRAILR01CA173453 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI EL-DEIRY, WAFIK S. · 2013 to 2023
$4.3MInvestigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted TherapyR01CA259188 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Yibin Yang · 2021 to 2026
$2.5MAnalysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin LymphomaR01CA251674 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI YANG, YIBIN · 2021 to 2025
$2.1MOptimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patientsU01CA260369 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ABBOSH, PHILIP · 2021 to 2025
$2.0MNCI NIH HHS P30 CA006927NCI NIH HHS R01 CA173453NCI NIH HHS R01 CA251674NCI NIH HHS R01 CA259188NCI NIH HHS U01 CA260369NCI NIH HHS U54 CA221705NIDCR NIH HHS P50 DE030707
6 · The paper itselfAbstract
Background: Supply chain disruptions during the COVID-19 pandemic have affected the availability of components for specimen collection kits to detect SARS-CoV-2. Plastic injection molding offers a rapid and cheap method for mass production of swabs for upper respiratory tract sampling. Local production of virus transport medium increases flexibility to assemble sample collection kits if the medium provides appropriate stability for SARS-CoV-2 detection. Methods: A locally produced virus transport medium and a novel injection molded plastic swab were validated for SARS-CoV-2 detection by reverse-transcription quantitative polymerase chain reaction. Both components were compared to standard counterparts using viral reference material and representative patient samples. Results: Clinical testing showed no significant differences between molded and flocked swabs. Commercial and in-house virus transport media provided stable test results for over 40 days of specimen storage and showed no differences in test results using patient samples. Conclusions: This collection kit provides new supply chain options for SARS-CoV-2 testing.
Indexed as
COVID-19NeoplasmsCOVID-19 TestingCulture MediaHumansNasopharynxPandemicsRNA, ViralSARS-CoV-2Specimen HandlingCulture MediaRNA, Viralalternative collection swabSARS-CoV-2 RT-qPCRviral stability
Identifiers
PMID36910578
PMCPMC10001927
OpenAlexW4310725135
What OpenQuestion holds
Textmetadata
Read underepoch 390